ESYT2: A Potential Drug Target Or Biomarker (G57488)

Target Name: ESYT2

NCBI ID: G57488

ESYT2

ESYT2: A Potential Drug Target Or Biomarker

ESYT2 (Erythropoietin Gene 2) is a gene that encodes for a protein known as erythropoietin (EPO), which is a protein found in red blood cells that is responsible for the production of new red blood cells in the body. EPO is critical for maintaining the production of normal red blood cells, which are responsible for carrying oxygen from the lungs to the rest of the body.

One of the unique features of ESYT2 is its location on the genetic map. It is located on chromosome 17, specifically on position 168.3. This makes it a potential target for researchers who are looking for new drug compounds or biomarkers for various diseases.

In addition to its role in red blood cell production, ESYT2 has also been shown to play a role in the development and progression of certain diseases. For example, studies have shown that ESYT2 is often expressed at higher levels in individuals with certain types of cancer, such as leukemia and multiple myeloma.

Furthermore, ESYT2 has also been shown to be involved in the regulation of cellular processes that are important for the growth, development, and survival of cancer cells. This makes it a potential target for new anti-cancer drugs that can inhibit the activity of ESYT2 and its downstream targets.

In conclusion, ESYT2 is a gene that has the potential to be a drug target or biomarker for various diseases. Further research is needed to determine its exact role in the development and progression of cancer, as well as its potential as a therapeutic target.

Protein Name: Extended Synaptotagmin 2

Functions: Tethers the endoplasmic reticulum to the cell membrane and promotes the formation of appositions between the endoplasmic reticulum and the cell membrane. Binds glycerophospholipids in a barrel-like domain and may play a role in cellular lipid transport. Plays a role in FGF signaling via its role in the rapid internalization of FGFR1 that has been activated by FGF1 binding; this occurs most likely via the AP-2 complex. Promotes the localization of SACM1L at endoplasmic reticulum-plasma membrane contact sites (EPCS) (PubMed:27044890)

The "ESYT2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ESYT2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets